Factors contributing to the prevalence of potential drug-drug interactions among hospitalized elderly patients in a tertiary hospital in Eastern Java, Indonesia

Shah Faisal; Junaidi Khotib; Cahyo Wibisono; Khusnul Fitri Hamidah; Febriansyah Nur Utomo; Elida Zairina

doi:10.13181/mji.oa.257888

Authors

Shah Faisal Department of Pharmacy, CECOS University of IT and Emerging Sciences, Peshawar, Pakistan
Junaidi Khotib Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
Cahyo Wibisono Universitas Airlangga Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Khusnul Fitri Hamidah Universitas Airlangga Hospital, Surabaya, Indonesia
Febriansyah Nur Utomo Universitas Airlangga Hospital, Surabaya, Indonesia
Elida Zairina Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; Innovative Pharmacy Practice and Integrated Outcome Research (INACORE) Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; Center of Excellence for Patient Safety and Quality, Universitas Airlangga, Surabaya, Indonesia

DOI:

https://doi.org/10.13181/mji.oa.257888

Keywords:

chronic disease, drug interactions, elderly, polypharmacy

Abstract

BACKGROUND Drug-drug interactions (DDIs) are the primary cause of adverse drug events. However, studies on potential DDIs (pDDIs) in hospitalized older adult patients in Indonesia remain limited. Therefore, this study aimed to investigate the prevalence and potential risk factors of pDDIs in this population.

METHODS A prospective observational study assessing the medical profiles of hospitalized elderly patients was conducted at Universitas Airlangga Hospital from September 2023 to February 2024. Patient characteristics were recorded, and Micromedex® Drug-Reax software was used to check the pDDIs. Ethical approval was obtained for this study (No. 078/KEP/2023). Data were analyzed using SPSS software (version 26).

RESULTS Of the 409 patients, 41.9% of the prescriptions contained pDDIs. Furthermore, 73 prescriptions (17.1%) had at least one pDDI, with 1–6 interactions per prescription. Of the 369 identified pDDIs, 209 (56.6%) were major interactions. Logistic regression analysis revealed increased odds of pDDIs in patients with previous medication use (adjusted odds ratio [aOR] = 2.254; crude odds ratio (cOR] = 1.771), polypharmacy (aOR = 16.309; cOR = 11.709), circulatory diseases (aOR = 4.082; cOR = 4.788), and genitourinary diseases (aOR = 1.819; cOR = 1.855). Conversely, patients with digestive system diseases had a significantly lower risk (aOR = 0.573; cOR = 0.608).

CONCLUSIONS This study found a high prevalence of pDDIs (41.1%) among older hospitalized patients in Indonesia. Modifiable factors, such as polypharmacy and previous medication use, can reduce the risk of pDDIs and avoid adverse events.

Downloads

Download data is not yet available.

References

Basrowi RW, Rahayu EM, Khoe LC, Wasito E, Sundjaya T. The road to healthy ageing: what has Indonesia achieved so far? Nutrients. 2021;13(10):3441. https://doi.org/10.3390/nu13103441

Saedder EA, Lisby M, Nielsen LP, Bonnerup DK, Brock B. Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. Br J Clin Pharmacol. 2015;80(4):808-17. https://doi.org/10.1111/bcp.12600

Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi (India): Jaypee Brothers Medical Publishers Pvt Ltd; 2019.

Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin epidemiol. 2018;10:289-98. https://doi.org/10.2147/CLEP.S153458

Wastesson JW, Morin L, Tan EC, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185-96. https://doi.org/10.1080/14740338.2018.1546841

Reinhild Haerig T, Krause D, Klaassen-Mielke R, Rudolf H, Trampisch HJ, Thuermann P. Potentially inappropriate medication including drug-drug interaction and the risk of frequent falling, hospital admission, and death in older adults-results of a large cohort study (getABI). Front Pharmacol. 2023;14:1062290. https://doi.org/10.3389/fphar.2023.1062290

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74. https://doi.org/10.1186/s12916-015-0322-7

Alemayehu TT, Wassie YA, Bekalu AF, Tegegne AA, Ayenew W, Tadesse G, et al. Prevalence of potential drug-drug interactions and associated factors among elderly patients in Ethiopia: a systematic review and meta-analysis. Glob Health Res Policy. 2024;9(1):46. https://doi.org/10.1186/s41256-024-00386-7

Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatr. 2021;21(1):233. https://doi.org/10.1186/s12877-021-02183-0

Janković SM, Pejčić AV, Milosavljević MN, Opančina VD, Pešić NV, Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018;43:1-6. https://doi.org/10.1016/j.jcrc.2017.08.021

Bakker T, Abu-Hanna A, Dongelmans DA, Vermeijden WJ, Bosman RJ, de Lange DW, et al. Clinically relevant potential drug-drug interactions in intensive care patients: a large retrospective observational multicenter study. J Crit Care. 2021;62:124-30. https://doi.org/10.1016/j.jcrc.2020.11.020

Jazbar J, Locatelli I, Horvat N, Kos M. Clinically relevant potential drug-drug interactions among outpatients: a nationwide database study. Res Social Adm Pharm. 2018;14(6):572-80. https://doi.org/10.1016/j.sapharm.2017.07.004

Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15-27. https://doi.org/10.1007/s00228-017-2357-5

Ayalew MB, Tegegn HG, Abdela OA. Drug related hospital admissions; a systematic review of the recent literatures. Bull Emerg Trauma. 2019;7(4): 339-46. https://doi.org/10.29252/beat-070401

Maharani L, Yugatama A. Prevalence of adverse drug reaction in Indonesia: a systematic review. J Appl Pharm Sci. 2023;13(8):055-67. https://doi.org/10.7324/JAPS.2023.91550

Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71(2):131-42. https://doi.org/10.1007/s00228-014-1786-7

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? a systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. https://doi.org/10.1001/jama.2013.281053

Shetty V, Chowta MN, Chowta KN, Shenoy A, Kamath A, Kamath P. Evaluation of potential drug-drug interactions with medications prescribed to geriatric patients in a tertiary care hospital. J Aging Res. 2018;1:5728957. https://doi.org/10.1155/2018/5728957

Saraswati MD, Ardiana SM, Suprapti B, Assegaf MY, Suharjono S, Hamidah KF. Potential drug-drug interactions in ambulatory patients with hypertension: a retrospective study. JPPS. 2022;9(1):69-74. https://doi.org/10.20473/jfiki.v9i12022.69-74

Osikoya O, Jaini PA, Nguyen A, Valdes M, Goulopoulou S. Effects of low-dose aspirin on maternal blood pressure and vascular function in an experimental model of gestational hypertension. Pharmacol Res. 2017;120:267-78. https://doi.org/10.1016/j.phrs.2017.04.012

Hermann M, Carstens N, Kvinge L, Fjell A, Wennersberg M, Folleso K, et al. Polypharmacy and potential drug-drug interactions in home-dwelling older people-a cross-sectional study. J Multidiscip Healthc. 2021;14:589-97. https://doi.org/10.2147/JMDH.S297423

Salwe KJ, Kalyansundaram D, Bahurupi Y. A study on polypharmacy and potential drug-drug interactions among elderly patients admitted in department of medicine of a tertiary care hospital in Puducherry. J Clin Diagn Res. 2016;10(2):FC06-10. https://doi.org/10.7860/JCDR/2016/16284.7273

Wolff J, Hefner G, Normann C, Kaier K, Binder H, Hiemke C, et al. Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. Pharmacoepidemiol Drug Saf. 2021;30(9):1258-68. https://doi.org/10.1002/pds.5310

Zerah L, Henrard S, Wilting I, O'Mahony D, Rodondi N, Dalleur O, et al. Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial. BMC Geriatr. 2021;21(1):571. https://doi.org/10.1186/s12877-021-02532-z

Nusair MB, Al-Azzam SI, Arabyat RM, Amawi HA, Alzoubi KH, Rabah AA. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J. 2020;28(2):155-60. https://doi.org/10.1016/j.jsps.2019.11.009

Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2010;8(1):13-28. https://doi.org/10.1038/nrcardio.2010.162